Navigation Links
Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Date:5/15/2012

MADISON, Wis., May 15, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.  The first two-patient cohort was successfully dosed with approximately 20 mCi of HOT, triggering enrollment into the second cohort at approximately 40 mCi.  Details of the trial design are available on www.clinicaltrials.gov ID: NCT01495663, or at www.novelos.com in the 'Clinical Trials' section.  Glenn Liu, M.D., University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.  Detailed trial results are expected to be presented at a scientific venue at a later date.

"Patients with advanced solid tumors need safer and more effective therapies," said Dr. Liu.  "Based on animal data, results from a completed Phase 1a dosimetry trial, and now initial data from this Phase 1b trial, HOT appears to deliver radiation directly and selectively to cancerous tumors.  Data from the first cohort indicates HOT was well-tolerated, without any grade 3 or 4 toxicities, enabling enrollment of the first patient in the second cohort.  HOT uptake in cancerous tumors persisted for at least 21 days.  One patient with advanced prostate cancer remains on trial at two months following treatment with HOT, while another patient with advanced colorectal cancer has completed the trial."

"We are pleased with HOT's safety profile and selective cancerous tumor uptake and retention in this first cohort at a dose of approximately 20 mCi," said Kim Hawkins, Vice President of Clinical Development of Novelos.  "We
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Prices $5.9 Million Public Offering
3. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
4. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
5. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
8. Echo Therapeutics Announces First Quarter 2012 Financial Results
9. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 15, 2011 XTIO2 INC . ... the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM ... XTI™  Nano-Facemask . It is the world,s most ... transmitted via air and contact surfaces. The unique nanocoating ...
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading ... disorders, today announced that researchers at Samuel Merritt University ... Grant to study the effects of wearing a strategically ... with MS. This grant comes after ...
Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... tool developed at the University of Utah (U of ... in three separate cases, U of U researchers and ... The American Journal of Human Genetics . The software, ... illnesses and unknown gene mutations by analyzing the exomes, ... genes are made, in individual patients and small families. ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... of Buffalo had said that postmenopausal women would have lesser ... periodontal disease at bay. Their research was published in the ... studied 106 postmenopausal women had found that in an average ... one tooth. Their research says that alveolar bone loss is ...
... A nine-year-old boy in a West Bengal town is said to ... his Rip Van Winkle act. // ,Reports Saturday said Arup ... playful boy of eight until 11 months ago when he suddenly ... and recite very well, can now only be half awakened for ...
... Z-Trim fat replacer at a recent show //in New Orleans. ... variety of products without altering the food's original taste. ... Z-Trim fat replacer at a recent show in New Orleans. ... symposia and 14,000 attendees. , ,According to the manufacturers, ...
... small packages. So are the twin electroneedles, which is ... heart attack episodes. The two arrays of micron-sized ... ,Good thing come in small packages. So are ... also said to benefit high-risk cardiac patients by confirming ...
... remains one of the significant health problems to be ... faceted approach. A protein-based diet could help in improving ... shows that consuming a protein hydrolysate and amino acid ... diabetics, and could therefore help individuals control their blood ...
... couples who smoke according to a new study// which has ... than cigarette-smoking women with non-smoking spouses. ,The study recorded ... stroke and ischemic stroke (a stroke caused by a blood ... of women. The relative risk of total stroke was 5.7 ...
Cached Medicine News:Health News:New Insight In Periodontal Disease In Postmenopausal Women 2Health News:New Oat And Soy-Based Fat Replacer Launched 2Health News:Diabetes and heart attack diagnosis now made simple with twin magic 2Health News:Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: